Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma

被引：9

作者：

Lei, Zhengqing ^{[1
]}

Ma, Weihu ^{[1
]}

Si, Anfeng ^{[2
]}

Zhang, Yuhua ^{[3
]}

Yang, Facai ^{[1
]}

Yu, Qiushi ^{[1
]}

Tang, Haolan ^{[1
]}

Xiao, Qianru ^{[1
]}

Zhou, Jiahua ^{[1
]}

Wang, Kui ^{[4
]}

Tang, Yufu ^{[5
]}

Han, Tao ^{[6
]}

Yin, Guowen ^{[7
]}

Chen, Jinhong ^{[8
,9
]}

Liu, Xiufeng ^{[10
]}

Zhao, Hua ^{[11
]}

Yu, Decai ^{[12
]}

Luo, Tao ^{[13
,14
]}

Wang, Qing ^{[15
]}

Yan, Maolin ^{[16
]}

Mao, Xianhai ^{[17
]}

Li, Jing ^{[18
]}

Wang, Kai ^{[19
]}

Li, Jingdong ^{[20
]}

Zeng, Yongyi ^{[21
]}

Ding, Dequan ^{[22
]}

Chen, Tingsong ^{[23
]}

Wu, Xiaofeng ^{[24
]}

Xia, Yongxiang ^{[24
]}

Wang, Kang ^{[25
]}

Guo, Weixing ^{[25
]}

Zhu, Guangyu ^{[26
]}

Gao, Shan ^{[27
]}

Hueser, Norbert ^{[28
]}

Lau, Wan Y. ^{[29
]}

Song, Tianqiang ^{[30
]}

Cheng, Shuqun ^{[25
]}

Shen, Feng ^{[31
]}

Cheng, Zhangjun ^{[1
]}

机构：

[1] Southeast Univ, Zhongda Hosp, Hepatopancreatobiliary Ctr, Sch Med, Nanjing 210009, Peoples R China

[2] Nanjing Med Univ, Dept Surg Oncol, Qin Huai Med Dist, Jinling Hosp, Nanjing, Peoples R China

[3] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Surg,Inst Basic Med, Hangzhou, Peoples R China

[4] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 2, Shanghai, Peoples R China

[5] Northern Theater Command, Dept Hepatobiliary Surg, Gen Hosp, Shenyang, Peoples R China

[6] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China

[7] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Intervent Radiol Dept,Affiliated Canc Hosp, Nanjing, Peoples R China

[8] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China

[9] Fudan Univ, Canc Metastasis Inst, Shanghai, Peoples R China

[10] Jinling Hosp, Dept Med Oncol, PLA Canc Ctr, Nanjing, Peoples R China

[11] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou, Peoples R China

[12] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Med Sch, Nanjing, Peoples R China

[13] Third Mil Med Univ, Army Med Univ, Inst Pathol, Minist Educ China,Key Lab Tumor Immunopathol, Chongqing, Peoples R China

[14] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Chongqing, Peoples R China

[15] Zibo Cent Hosp, Dept Gen Surg, Zibo, Peoples R China

[16] Fujian Prov Hosp, Dept Hepatobiliary Pancreat Surg, Fuzhou, Peoples R China

[17] Hunan Normal Univ, Hunan Prov Peoples Hosp, Dept Hepatobiliary Surg, Affiliated Hosp 1, Changsha, Peoples R China

[18] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, Chongqing, Peoples R China

[19] Nanchang Univ, Jiangxi Prov Clin Res Ctr Gen Surg Dis, Dept Gen Surg, Affiliated Hosp 2, Nanchang, Peoples R China

[20] North Sichuan Med Coll, Dept Hepatobiliary Surg, Affiliated Hosp, Nanchong, Peoples R China

[21] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary Surg, Fuzhou, Peoples R China

[22] Maanshan Peoples Hosp, Dept Intervent Radiol, Maanshan, Peoples R China

[23] Shanghai Univ Tradit Chinese Med, Dept Oncol, Peoples Hosp 7, Shanghai, Peoples R China

[24] Nanjing Med Univ, Chinese Acad Med Sci, Hepatobiliary Ctr, Affiliated Hosp 1,Key Lab Liver Transplantat,NHC K, Nanjing, Peoples R China

[25] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China

[26] Southeast Univ, Zhongda Hosp, Ctr Intervent Radiol & Vasc Surg, Sch Med,Dept Radiol, Nanjing, Peoples R China

[27] Southeast Univ, Zhongda Hosp, Adv Inst Life & Hlth, Sch Life Sci & Technol, Nanjing, Peoples R China

[28] Tech Univ Munich, TUM Sch Med, Dept Surg, Klinikum Rechts Isar, Munich, Germany

[29] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China

[30] Tianjin Med Univ Canc Inst & Hosp, Liver Canc Ctr, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin 300060, Peoples R China

[31] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai 200438, Peoples R China

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 58卷 / 06期

基金：

中国国家自然科学基金;

关键词：

chemotherapy; combination therapy; immune checkpoint inhibitor; immunotherapy; intrahepatic cholangiocarcinoma; HEPATOCELLULAR-CARCINOMA; OPEN-LABEL; PLUS; BEVACIZUMAB;

D O I：

10.1111/apt.17623

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Immune checkpoint inhibitor (ICI) combination therapy offers a new option for treatment of unresectable intrahepatic cholangiocarcinoma (uICC).Aim: To compare the effect of different anti-PD-1 combination therapies as the first-line treatments for uICC.Methods: This study included 318 patients who received chemotherapy alone (Chemo), anti-PD-1 plus chemotherapy (ICI-chemo), anti-PD-1 plus targeted therapy (ICI-target) or anti-PD-1 plus targeted therapy and chemotherapy (ICI-target-chemo) as first line for uICC from 22 centres in China. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR) and safety.Results: Patients with ICI-chemo (median PFS [mPFS], 6.3 months; HR: 0.61, 95% CI: 0.42-0.88; p = 0.008; median OS [mOS], 10.7 months; HR: 0.61, 95% CI: 0.39-0.94; p = 0.026), ICI-target (7.2 months; HR: 0.54, 95% CI: 0.36-0.80; p = 0.002; 15.8 months; HR: 0.54, 95% CI: 0.35-0.84; p = 0.006) or ICI-target-chemo (6.9 months; HR: 0.65, 95% CI: 0.47-0.90; p = 0.009; 14.4 months; HR: 0.47, 95% CI: 0.31-0.70; p < 0.001) achieved better clinical outcomes than those with Chemo (3.8 months; 9.3 months). ICI-target was not inferior to ICI-chemo in survival outcomes (HR for PFS: 0.88, 95% CI: 0.55-1.42; p = 0.614; HR for OS: 0.89, 95% CI: 0.51-1.55; p = 0.680). ICI-target-chemo yielded similar prognoses as ICI-chemo (HR for PFS: 1.07, 95% CI: 0.70-1.62; p = 0.764; HR for OS: 0.77, 95% CI: 0.45-1.31; p = 0.328) and ICI-target (HR for PFS: 1.20, 95% CI: 0.77-1.88; p = 0.413; HR for OS: 0.86, 95% CI: 0.51-1.47; p = 0.583) but resulted in more adverse events (p < 0.001; p = 0.010). Multivariable and propensity score analyses supported these findings.Conclusions: Among patients with uICC, ICI-chemo or ICI-target provided more survival benefits than Chemo while achieving comparable prognoses and fewer adverse events than ICI-target-chemo.

引用

页码：611 / 622

页数：12

共 50 条

[1] Evaluating triple therapy with lenvatinib, PD-1 inhibitor and transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma: A retrospective study
Tu, Jianfei
Ying, Xihui
Lai, Lingqiang
Huang, Chaoming
Liu, Shuang
Chen, Li
Zhang, Dengke
Wu, Jiahao
Chen, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
Xie, Lulu
Huang, Jingzheng
Wang, Linling
Ren, Wenrui
Tian, Hao
Hu, Anhong
Liang, Jun
Jiao, Yuqing
Li, Yali
Zhou, Qunfang
Zhang, Wenjing
FRONTIERS IN PHARMACOLOGY, 2022, 13
[3] Effectiveness and safety of transarterial chemoembolization combined with PD-1 inhibitors and lenvatinib for unresectable intrahepatic cholangiocarcinoma
Huang, Jin-Tao
Hu, Di
Hong, Xin
Zhou, Wen-Jie
Shen, Jian
Lv, Peng-Hua
Zhu, Xiao-Li
EUROPEAN RADIOLOGY EXPERIMENTAL, 2025, 9 (01)
[4] Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma
O'Donnell, Conor D. J.
Majeed, Umair
Rutenberg, Michael S.
Croome, Kristopher P.
Poruk, Katherine E.
Toskich, Beau
Jin, Zhaohui
CURRENT ONCOLOGY, 2025, 32 (02)
[5] Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma
Ni, Jia-yan
Sun, Hong-liang
Guo, Ge-fan
Zhou, Xiong
Wei, Jin-xing
Xu, Lin-feng
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 140
[6] Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
Yang, Zhenyun
Zhang, Deyao
Zeng, Huilan
Fu, Yizhen
Hu, Zili
Pan, Yangxun
Chen, Jinbin
Wang, Juncheng
Zhang, Yaojun
Zhou, Zhongguo
Xu, Li
Hu, Dandan
Chen, Minshan
JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 5721 - 5731
[7] Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
Zhu, Meiyan
Jin, Meng
Zhao, Xiao
Shen, Shunli
Chen, Yihan
Xiao, Han
Wei, Guangyan
He, Qiang
Li, Bin
Peng, Zhenwei
BMC MEDICINE, 2024, 22 (01)
[8] Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma
Yang, Zhenyun
Zhang, Deyao
Sima, Xiaoxian
Fu, Yizhen
Zeng, Huilan
Hu, Zili
Hou, Jingyu
Pang, Yangxun
Zhang, Yaojun
Zhou, Zhongguo
Chen, Minshan
Hu, Dandan
INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
[9] Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma
Hong, Kelvin
Geschwind, Jean-Francois H.
SEMINARS IN ONCOLOGY, 2010, 37 (02) : 110 - 117
[10] PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
Zhang, Hong-Qiang
Huang, Chang-Zhi
Wu, Jing-Yu
Wang, Zhen-Ling
Shao, Yu
Fu, Zan
WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (14) : 4669 - 4675

← 1 2 3 4 5 →